Login Register Cart 0
Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Prevalence of Anti-nuclear and Anti-phospholipid Antibodies in an Egyptian Cohort with Schizophrenia: A Case-control Study

Author(s): Basma M. Medhat*, Mohammed H. Abu-Zaid, Dalia Dorgham, Nehal El-Ghobashy, Angie Y. Afifi, Shirin El-Makawi, Doaa R. Ayoub, Ola O. Khalaf, Reham Amer, Dina M.T. Koptan and Lobna A. Maged

Volume 18, Issue 3, 2022

Published on: 11 January, 2022

Page: [266 - 271] Pages: 6

DOI: 10.2174/1573397117666211109115120

Price: $65

Abstract

Background: Psychiatric disorders, including schizophrenia, could herald other manifestation( s) of systemic lupus erythematosus (SLE) potentially hindering timely and optimal management. Moreover, schizophrenia is among the described ‘extra-criteria’ manifestations of anti-phospholipid syndrome (APS). Hence, screening schizophrenia patients for SLE and APS may pose diagnostic and therapeutic implications.

Objectives: Examine schizophrenia patients with no overt connective tissue disease(s) manifestation( s) for clinical and/or serologic evidence of SLE and/or APS.

Methods: The study included 92 schizophrenia patients (61 (66.3%) males) and 100 age- and gender- matched healthy controls. Both groups were tested for anti-nuclear antibodies (ANAs), antidouble stranded deoxyribonucleic acid (anti-dsDNA) antibodies, complement 3 (C3) and C4, and criteria anti-phospholipid antibodies (aPL) (anticardiolipin Immunoglobulin (Ig) G and IgM, antibeta- 2-glycoprotein I IgG and IgM, and lupus anticoagulant (LAC)).

Results: The patients’ mean age and disease duration were 28.8 ± 8.1 and 5.7 ± 2.2 years, respectively. The prevalence of ANA positivity, height of titre, and pattern was comparable between patients and controls (p = 0.9, p = 0.8 and p = 0.1, respectively). Anti-dsDNA antibodies and hypocomplementemia were absent in both groups. A significantly higher frequency of positive LAC was observed among patients compared with controls (7.6% vs. 1%, p = 0.02), whereas other aPL were comparable between both groups. None of the patients or controls demonstrated clinically meaningful (medium or high) aPL titres.

Conclusion: In our study, schizophrenia was solely associated with LAC. Thus, in the absence of findings suggestive of SLE or APS, routine screening for both diseases is questionable.

Keywords: Anti-nuclear antibodies, anti-phospholipid antibodies, anti-phospholipid syndrome, neuropsychiatric, psychosis, schizophrenia, systemic lupus erythematosus.

« Previous Next »
[1]
Wang LY, Chen SF, Chiang JH, Hsu CY, Shen YC. Autoimmune diseases are associated with an increased risk of schizophrenia: A nationwide population-based cohort study. Schizophr Res 2018; 202: 297-302.
[http://dx.doi.org/10.1016/j.schres.2018.06.033] [PMID: 29925476]
[2]
Benros ME, Eaton WW, Mortensen PB. The epidemiologic evidence linking autoimmune diseases and psychosis. Biol Psychiatry 2014; 75(4): 300-6.
[http://dx.doi.org/10.1016/j.biopsych.2013.09.023] [PMID: 24199668]
[3]
Ripke S, Neale BM, Corvin A, Walters JT, Farh KH, Holmans PA, et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511(7510): 421-7.
[http://dx.doi.org/10.1038/nature13595] [PMID: 25056061]
[4]
Sekar A, Bialas AR, de Rivera H, et al. Schizophrenia risk from complex variation of complement component 4. Nature 2016; 530(7589): 177-83.
[http://dx.doi.org/10.1038/nature16549] [PMID: 26814963]
[5]
Chiang SSW, Riedel M, Schwarz M, Mueller N. Is T-helper type 2 shift schizophrenia-specific? Primary results from a comparison of related psychiatric disorders and healthy controls. Psychiatry Clin Neurosci 2013; 67(4): 228-36.
[http://dx.doi.org/10.1111/pcn.12040] [PMID: 23683153]
[6]
Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry 1999; 4(4): 317-27.
[http://dx.doi.org/10.1038/sj.mp.4000586] [PMID: 10483047]
[7]
Maes M. Cytokines in schizophrenia. Biol Psychiatry 1997; 42(4): 308-9.
[http://dx.doi.org/10.1016/S0006-3223(97)00240-0] [PMID: 9270912]
[8]
Pollak TA, Rogers JP, Nagele RG, et al. Antibodies in the Diagnosis, Prognosis, and Prediction of Psychotic Disorders. Schizophr Bull 2019; 45(1): 233-46.
[http://dx.doi.org/10.1093/schbul/sby021] [PMID: 29474698]
[9]
Bechter K, Reiber H, Herzog S, Fuchs D, Tumani H, Maxeiner HG. Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction. J Psychiatr Res 2010; 44(5): 321-30.
[http://dx.doi.org/10.1016/j.jpsychires.2009.08.008] [PMID: 19796773]
[10]
Regina P, Pnina R, Natur A, Yair L. Anti-phospholipid syndrome associated with schizophrenia description of five patients and review of the literature. Immunol Res 2017; 65(2): 438-46.
[http://dx.doi.org/10.1007/s12026-017-8895-1] [PMID: 28102512]
[11]
Brey RL, Escalante A. Neurological manifestations of antiphospholipid antibody syndrome. Lupus 1998; 7(2)(Suppl. 2): S67-74.
[http://dx.doi.org/10.1177/096120339800700216] [PMID: 9814677]
[12]
Raza H, Epstein SA, Pao M, Rosenstein DL. Mania: psychiatric manifestations of the antiphospholipid syndrome. Psychosomatics 2008; 49(5): 438-41.
[http://dx.doi.org/10.1176/appi.psy.49.5.438] [PMID: 18794513]
[13]
Sanna G, D’Cruz D, Cuadrado MJ. Cerebral manifestations in the antiphospholipid (Hughes) syndrome. Rheum Dis Clin North Am 2006; 32(3): 465-90.
[http://dx.doi.org/10.1016/j.rdc.2006.05.010] [PMID: 16880079]
[14]
Gilburd B, Stein M, Tomer Y, et al. Autoantibodies to phospholipids and brain extract in patients with the Guillain-Barre syndrome: cross-reactive or pathogenic? Autoimmunity 1993; 16(1): 23-7.
[http://dx.doi.org/10.3109/08916939309010644] [PMID: 8136463]
[15]
Tanne D, Hassin-Baer S. Neurologic manifestations of the antiphospholipid syndrome. Curr Rheumatol Rep 2001; 3(4): 286-92.
[http://dx.doi.org/10.1007/s11926-001-0032-3] [PMID: 11470046]
[16]
Cervera R, Boffa MC, Khamashta MA, Hughes GRV. The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus 2009; 18(10): 889-93.
[http://dx.doi.org/10.1177/0961203309106832] [PMID: 19671788]
[17]
Islam MA, Alam F, Cavestro C, et al. Antiphospholipid antibodies in epilepsy: A systematic review and meta-analysis. Autoimmun Rev 2018; 17(8): 755-67.
[http://dx.doi.org/10.1016/j.autrev.2018.01.025] [PMID: 29885542]
[18]
Islam MA, Alam F, Wong KK. Comorbid association of antiphospholipid antibodies and migraine: A systematic review and meta-analysis. Autoimmun Rev 2017; 16(5): 512-22.
[http://dx.doi.org/10.1016/j.autrev.2017.03.005] [PMID: 28279839]
[19]
Cohn JB, Karnosh LJ, Stecher RM. Clinical trials with cortisone in the treatment of chronic schizophrenia. Dis Nerv Syst 1951; 12(10): 291-5.
[PMID: 14887571]
[20]
Rees L, King GM. Intensive cortisone therapy in schizophrenia. J Ment Sci 1956; 102(426): 155-9.
[http://dx.doi.org/10.1192/bjp.102.426.155] [PMID: 13307195]
[21]
Polatin P, Lesse S, Harris MM. Use of large doses of cortisone in schizophrenia; clinical, physiological, and metabolic observations. AMA Arch Neurol Psychiatry 1955; 73(5): 485-95.
[http://dx.doi.org/10.1001/archneurpsyc.1955.02330110001001] [PMID: 14360864]
[22]
Nasib LG, Sommer IE, Winter-van Rossum I, et al. Prednisolone versus placebo addition in the treatment of patients with recent-onset psychotic disorder: a trial design. Trials 2020; 21(1): 492.
[http://dx.doi.org/10.1186/s13063-020-04365-4] [PMID: 32513294]
[23]
Mack A, Pfeiffer C, Schneider EM, Bechter K. Schizophrenia or atypical lupus erythematosus with predominant psychiatric manifestations over 25 years: case analysis and review. Front Psychiatry 2017; 8: 131.
[http://dx.doi.org/10.3389/fpsyt.2017.00131] [PMID: 28798699]
[24]
Hoirisch-Clapauch S, Nardi AE. Psychiatric remission with warfarin: Should psychosis be addressed as plasminogen activator imbalance? Med Hypotheses 2013; 80(2): 137-41.
[http://dx.doi.org/10.1016/j.mehy.2012.11.011] [PMID: 23211375]
[25]
Hanly JG, Li Q, Su L, et al. Psychosis in systemic lupus erythematosus: results from an international inception cohort study. Arthritis Rheumatol 2019; 71(2): 281-9.
[http://dx.doi.org/10.1002/art.40764] [PMID: 30375754]
[26]
Hanly JG, Urowitz MB, Su L, et al. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2010; 69(3): 529-35.
[http://dx.doi.org/10.1136/ard.2008.106351] [PMID: 19359262]
[27]
Fan W, Zhou Z, Lu L, Chen S, Bao C. Clinical manifestations of neuropsychiatric systemic lupus erythematosus in Chinese patients. Turkish J Rheumato 2014; 29(2): 88.
[28]
Funauchi M, Yamagata T, Nozaki Y, et al. A case of systemic lupus erythematosus that manifested in the course of schizophrenia. Scand J Rheumatol 2002; 31(6): 374-6.
[http://dx.doi.org/10.1080/030097402320817121] [PMID: 12492255]
[29]
Kumar P, Kumar A, Thakur V, Sharma CB, Thomas A, Chatterjee S. Acute psychosis as the presenting manifestation of lupus. J Family Med Prim Care 2021; 10(2): 1050-3.
[http://dx.doi.org/10.4103/jfmpc.jfmpc_1475_20] [PMID: 34041122]
[30]
Park E, Markx S, Askanase A. Four cases of lupus psychosis: comment on the article by Hanly et al. Arthritis Rheumatol 2020; 72(5): 861-3.
[http://dx.doi.org/10.1002/art.41209] [PMID: 31960598]
[31]
El Missiry A, Sorour A, Sadek A, Fahy T, Abdel Mawgoud M, Asaad T. Homicide and psychiatric illness: an Egyptian study. MD thesis. Cairo: Ain Shams University 2004.
[32]
First MB, Gibbon M, Spitzer RL, Benjamin LS, Williams JB. Structured clinical interview for DSM-IV axis ii personality disorders SCID-II. Washington American Psychiatric Association Pub 1997.
[33]
Quéméneur T, Lambert M, Hachulla E, et al. Significance of persistent antiphospholipid antibodies in the elderly. J Rheumatol 2006; 33(8): 1559-62.
[PMID: 16832847]
[34]
Reinstein E, Shoenfeld Y. Antiphospholipid syndrome and cancer. Clin Rev Allergy Immunol 2007; 32(2): 184-7.
[http://dx.doi.org/10.1007/s12016-007-0003-1] [PMID: 17916991]
[35]
Asherson RA, Cervera R. Antiphospholipid antibodies and infections. Ann Rheum Dis 2003; 62(5): 388-93.
[http://dx.doi.org/10.1136/ard.62.5.388] [PMID: 12695147]
[36]
Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 7(10): 1737-40.
[http://dx.doi.org/10.1111/j.1538-7836.2009.03555.x] [PMID: 19624461]
[37]
Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019; 78(6): 736-45.
[http://dx.doi.org/10.1136/annrheumdis-2019-215089] [PMID: 30926722]
[38]
Mantovani C, Louzada-Junior P, Nunes EA, de Figueiredo FP, Oliveira GR, Del-Ben CM. Antinuclear antibodies testing as a routine screening for systemic lupus erythematosus in patients presenting first-episode psychosis. Early Interv Psychiatry 2012; 6(3): 322-5.
[http://dx.doi.org/10.1111/j.1751-7893.2011.00339.x] [PMID: 22260390]
[39]
Ezeoke A, Mellor A, Buckley P, Miller B. A systematic, quantitative review of blood autoantibodies in schizophrenia. Schizophr Res 2013; 150(1): 245-51.
[http://dx.doi.org/10.1016/j.schres.2013.07.029] [PMID: 23953827]
[40]
Agmon-Levin N, Damoiseaux J, Kallenberg C, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 2014; 73(1): 17-23.
[http://dx.doi.org/10.1136/annrheumdis-2013-203863] [PMID: 24126457]
[41]
Van Mierlo HC, De Witte L, Derksen RH, Otten HG. The prevalence of antinuclear antibodies in patients with schizophrenia spectrum disorders: results from a large cohort study. npj Schizophrenia 2015; 1(1): 1-4.
[42]
Sæther SG, Rø ADB, Larsen JB, Vaaler A, Kondziella D, Reitan SK. Biomarkers of autoimmunity in acute psychiatric disorders. J Neuropsychiatry Clin Neurosci 2019; 31(3): 246-53.
[http://dx.doi.org/10.1176/appi.neuropsych.18040069] [PMID: 30888921]
[43]
Islam MA, Alam F, Kamal MA, Wong KK, Sasongko TH, Gan SH. ‘Non-criteria’neurologic manifestations of antiphospholipid syndrome: a hidden kingdom to be discovered. CNS Neurol Disord Drug Targets 2016; 15(10): 1253-65. [Formerly Curr Drug Targets CNS Neurol Disord].
[http://dx.doi.org/10.2174/1871527315666160920122750] [PMID: 27658514]
[44]
Cecchi I, Radin M, Rubini E, et al. Clinical manifestations in patients with antiphospholipid antibodies: Beyond thrombosis and pregnancy loss. Lupus 2021; 30(6): 884-92.
[http://dx.doi.org/10.1177/0961203321995248] [PMID: 33593163]
[45]
Schwartz M, Kormilachev M, Kushnir M, Weller B, Rochas M, Toubi E. Lupus anticoagulant and anticardiolipin antibodies in serum of patients treated with risperidone. J Clin Psychiatry 2009; 70(5): 769-71.
[http://dx.doi.org/10.4088/JCP.08l04572] [PMID: 19552873]
[46]
Yannitsi SG, Manoussakis MN, Mavridis AK, et al. Factors related to the presence of autoantibodies in patients with chronic mental disorders. Biol Psychiatry 1990; 27(7): 747-56.
[http://dx.doi.org/10.1016/0006-3223(90)90590-X] [PMID: 2328270]
[47]
Manoubi W, Samoud S, Mankaï A, El Kissi Y, Ali NBH, Ghedira I. The high prevalence of anticardiolipin antibodies and anti-b2 glycoprotein I in the acute phase of schizophrenia. Eur Psychiatry 2015; 30(S1): 1-1.
[http://dx.doi.org/10.1016/S0924-9338(15)31332-8]
[48]
Chengappa KN, Carpenter AB, Keshavan MS, et al. Elevated IGG and IGM anticardiolipin antibodies in a subgroup of medicated and unmedicated schizophrenic patients. Biol Psychiatry 1991; 30(7): 731-5.
[http://dx.doi.org/10.1016/0006-3223(91)90019-I] [PMID: 1683585]
[49]
Firer M, Sirota P, Schild K, Elizur A, Slor H. Anticardiolipin antibodies are elevated in drug-free, multiply affected families with schizophrenia. J Clin Immunol 1994; 14(1): 73-8.
[http://dx.doi.org/10.1007/BF01541177] [PMID: 8132739]
[50]
Sidhom O, Laadhar L, Zitouni M, et al. Spectrum of autoantibodies in Tunisian psychiatric inpatients. Immunol Invest 2012; 41(5): 538-49.
[http://dx.doi.org/10.3109/08820139.2012.685537] [PMID: 22612859]
[51]
Dimova S, Halacheva K, Dimov D, Nikolova M, Tolev T. Correlation between anticardiolipin and anti-beta2 glycoprotein I antibodies in schizophrenic patients. Trakia J Sci 2007; 5(2): 35-9.
[52]
Kuwana M, Okano Y, Kaburaki J, Tojo T, Medsger TA Jr. Racial differences in the distribution of systemic sclerosis-related serum antinuclear antibodies. Arthritis Rheum 1994; 37(6): 902-6.
[http://dx.doi.org/10.1002/art.1780370619] [PMID: 8003063]
[53]
Szodoray P, Szabó Z, Kapitány A, et al. Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun Rev 2010; 9(3): 140-3.
[http://dx.doi.org/10.1016/j.autrev.2009.04.006] [PMID: 19427413]
[54]
Aran A, Lin L, Finn LA, et al. Post-streptococcal antibodies are associated with metabolic syndrome in a population-based cohort. PLoS One 2011; 6(9): e25017.
[http://dx.doi.org/10.1371/journal.pone.0025017] [PMID: 21949836]
[55]
Cabrera de León A, Almeida González D, Almeida AA, et al. Factors associated with parietal cell autoantibodies in the general population. Immunol Lett 2012; 147(1-2): 63-6.
[http://dx.doi.org/10.1016/j.imlet.2012.06.004] [PMID: 22771341]
[56]
Ganguli R, Brar JS, Solomon W, Chengappa KN, Rabin BS. Altered interleukin-2 production in schizophrenia: association between clinical state and autoantibody production. Psychiatry Res 1992; 44(2): 113-23.
[http://dx.doi.org/10.1016/0165-1781(92)90046-6] [PMID: 1480677]
[57]
Schwartz M, Rochas M, Toubi E, Sharf B. The presence of lupus anticoagulant and anticardiolipin antibodies in patients undergoing long-term neuroleptic treatment. J Psychiatry Neurosci 1999; 24(4): 351-2.
[PMID: 10516804]
[58]
Antovic A, Bruzelius M. Impaired fibrinolysis in the antiphospholipid syndrome. In: Semin Thromb Hemost. Thieme Medical Publishers 2021.
[http://dx.doi.org/10.1055/s-0041-1725098]
[59]
Ferro D, Quintarelli C, Rasura M, Antonini G, Violi F. Lupus anticoagulant and the fibrinolytic system in young patients with stroke. Stroke 1993; 24(3): 368-70.
[http://dx.doi.org/10.1161/01.STR.24.3.368] [PMID: 8446971]
[60]
Melchor JP, Strickland S. Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost 2005; 93(4): 655-60.
[http://dx.doi.org/10.1160/TH04-12-0838] [PMID: 15841309]
[61]
Madani R, Hulo S, Toni N, et al. Enhanced hippocampal long-term potentiation and learning by increased neuronal expression of tissue-type plasminogen activator in transgenic mice. EMBO J 1999; 18(11): 3007-12.
[http://dx.doi.org/10.1093/emboj/18.11.3007] [PMID: 10357813]
[62]
Ito M, Nagai T, Kamei H, et al. Involvement of tissue plasminogen activator-plasmin system in depolarization-evoked dopamine release in the nucleus accumbens of mice. Mol Pharmacol 2006; 70(5): 1720-5.
[http://dx.doi.org/10.1124/mol.106.022467] [PMID: 16908600]
[63]
Canoso RT, Sise HS. Chlorpromazine-induced lupus anticoagulant and associated immunologic abnormalities. Am J Hematol 1982; 13(2): 121-9.
[http://dx.doi.org/10.1002/ajh.2830130204] [PMID: 6814243]
[64]
Canoso RT, de Oliveira RM, Nixon RA. Neuroleptic-associated autoantibodies. A prevalence study. Biol Psychiatry 1990; 27(8): 863-70.
[http://dx.doi.org/10.1016/0006-3223(90)90467-G] [PMID: 1970485]
[65]
Canoso RT, de Oliveira RM. Chlorpromazine-induced anticardiolipin antibodies and lupus anticoagulant: absence of thrombosis. Am J Hematol 1988; 27(4): 272-5.
[http://dx.doi.org/10.1002/ajh.2830270408] [PMID: 3128108]
[66]
Lillicrap DP, Pinto M, Benford K, Ford PM, Ford S. Heterogeneity of laboratory test results for antiphospholipid antibodies in patients treated with chlorpromazine and other phenothiazines. Am J Clin Pathol 1990; 93(6): 771-5.
[http://dx.doi.org/10.1093/ajcp/93.6.771] [PMID: 1971739]
[67]
Davis S, Kern HB, Asokan R. Antiphospholipid antibodies associated with clozapine treatment. Am J Hematol 1994; 46(2): 166-7.
[http://dx.doi.org/10.1002/ajh.2830460233] [PMID: 8172195]
[68]
Kanjolia A, Valigorsky JM, Joson-Pasion ML. Clozaril-induced lupus anticoagulant. Am J Hematol 1997; 54(4): 345-6.
[http://dx.doi.org/10.1002/(SICI)1096-8652(199704)54:4<345::AID-AJH21>3.0.CO;2-9] [PMID: 9092703]
[69]
Delluc A, Rousseau A, Le Galudec M, et al. Prevalence of antiphospholipid antibodies in psychiatric patients users and non-users of antipsychotics. Br J Haematol 2014; 164(2): 272-9.
[http://dx.doi.org/10.1111/bjh.12627] [PMID: 24383845]

Rights & Permissions Print Cite
Article Metrics
14
© 2024 Bentham Science Publishers | Privacy Policy